Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma
Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
Related Articles
Certain Breast Cancer Subtypes May Derive a Greater Benefit With Ribociclib Combo vs Chemo
Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review
Treatment intensification strategies are reshaping the treatment landscape of metastatic castration-resistant prostate cancer. Genomic, molecular, and clinical indicators should be used to identify the optimal…
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial | Journal of Clinical Oncology
Purpose For patients with metastatic hormone-sensitive prostate cancer (mHSPC), delaying progression to castration-resistant disease is important not only for overall survival (OS) but also for…
Overcoming recurrence – how research is bringing new hope for breast cancer patients
Overcoming recurrence – how research is bringing new hope for breast cancer patients
FDA Grants Fast Track Designation to IMM-1-104 in NRAS+ Advanced Melanoma
The FDA has granted fast track designation to IMM-1-104 for the treatment of advanced melanoma.
Integrating cancer into crisis: a global vision for action from WHO and partners
More than a billion people live in fragile, conflict-affected, and vulnerable settings requiring humanitarian support, where cancer is a substantial health issue. Despite its substantial…
The Oncology QCARD Initiative: Fostering efficient evaluation of initial real‐world data proposals
Purpose The oncology quality, characterization, and assessment of real-world data (Oncology QCARD) Initiative was formed to develop a set of minimum study design and data…
Final results of a multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma (the STRSPH study)
To report final results of a prospective study of stereotactic body radiotherapy (SBRT) in patients with previously untreated solitary primary hepatocellular carcinoma (HCC).
Omacetaxine and azacitidine for newly diagnosed patients with MDS and excess blasts
In this video, Daniel Pollyea, University of Colorado School of Medicine, Denver, CO, comments on the potential of combining omacetaxine and azacitidine for newly diagnosed…
